Department of Immunology, Oslo University Hospital, Oslo, Norway.
Faculty of Medicine, KG Jebsen Centre for B Cell Malignances, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Br J Haematol. 2022 Aug;198(3):556-573. doi: 10.1111/bjh.18285. Epub 2022 Jun 2.
Chronic lymphocytic leukaemia (CLL) is characterised by malignant mature-like B cells. Supportive to CLL cell survival is chronic B-cell receptor (BCR) signalling; however, emerging evidence demonstrates CLL cells proliferate in response to T-helper (Th) cells in a CD40L-dependent manner. We showed provision of Th stimulation via CD40L upregulated CD45 phosphatase activity and BCR signalling in non-malignant B cells. Consequently, we hypothesised Th cell upregulation of CLL cell CD45 activity may be an important regulator of CLL BCR signalling and proliferation. Using patient-derived CLL cells in a culture system with activated autologous Th cells, results revealed increases in both Th and CLL cell CD45 activity, which correlated with enhanced downstream antigen receptor signalling and proliferation. Concomitantly increased was the surface expression of Galectin-1, a CD45 ligand, and CD43, a CLL immunophenotypic marker. Galectin-1/CD43 double expression defined a proliferative CLL cell population with enhanced CD45 activity. Targeting either Galectin-1 or CD43 using silencing, pharmacology, or monoclonal antibody strategies dampened CD45 activity and CLL cell proliferation. These results highlight a mechanism where activated Th cells drive CLL cell BCR signalling and proliferation via Galectin-1 and CD43-mediated regulation of CD45 activity, identifying modulation of CD45 phosphatase activity as a potential therapeutic target in CLL.
慢性淋巴细胞白血病(CLL)的特征是恶性成熟样 B 细胞。慢性 B 细胞受体(BCR)信号支持 CLL 细胞的存活;然而,新出现的证据表明 CLL 细胞以 CD40L 依赖性的方式响应辅助性 T 细胞(Th)增殖。我们通过 CD40L 提供 Th 刺激,上调了非恶性 B 细胞中的 CD45 磷酸酶活性和 BCR 信号。因此,我们假设 Th 细胞上调 CLL 细胞的 CD45 活性可能是 CLL BCR 信号和增殖的重要调节因子。在使用激活的自体 Th 细胞的培养系统中使用患者来源的 CLL 细胞,结果显示 Th 细胞和 CLL 细胞的 CD45 活性均增加,这与增强的下游抗原受体信号和增殖相关。同时增加的是 Galectin-1(CD45 配体)和 CD43(CLL 免疫表型标志物)的表面表达。Galectin-1/CD43 双重表达定义了具有增强的 CD45 活性的增殖性 CLL 细胞群。使用沉默、药理学或单克隆抗体策略靶向 Galectin-1 或 CD43,可减弱 CD45 活性和 CLL 细胞增殖。这些结果强调了一种机制,即激活的 Th 细胞通过 Galectin-1 和 CD43 介导的 CD45 活性调节来驱动 CLL 细胞 BCR 信号和增殖,确定了调节 CD45 磷酸酶活性作为 CLL 的潜在治疗靶点。